Prof. Aw Tar Choon
Senior Consultant, Department of Laboratory Medicine, Changi General Hospital
Singapore
There are many antibody tests for SARS-CoV-2 in the market, with wide variability in performance, and the accuracy of a test depends on numerous factors. On 24 April 2020, the World Health Organization (WHO) issued the following guidance: “At this point in the pandemic, there is not enough evidence about the effectiveness of antibody-mediated immunity to guarantee the accuracy of an ‘immunity passport’ or ‘risk-free certificate.’” There has been many uncertainties regarding SARS-CoV-2 antibodies. Do antibodies confer reliable immunity? How long do antibodies confer immunity? How long is a patient infective? From when on is a patient protected?
In view of these challenges, we have invited Dr. Beatus Ofenloch-Haehnle from Roche Diagnostics to share insights on the Elecsys® Anti-SARS-CoV-2 and post-launch updates and Prof. Aw Tar Choon, Senior Consultant, Changi General Hospital, Singapore to share his experience and factors to consider when selecting SARS-CoV-2 assays, and its clinical applications.
Register to watch recording